Medical equipment company Intersect ENT has received the US Food and Drug Administration (FDA) approval for its steroid releasing sinus implant PROPEL Contour.
With an hourglass design, the implant allows treatment of patients with chronic sinusitis in the frontal and maxillary sinuses.
The latest approval enables use of the PROPEL line of steroid releasing implants to treat patients undergoing ethmoid, frontal or maxillary surgeries.
